Last updated: February 16, 2026
What Is the Product?
NDC 62011-0406 corresponds to Rilpivirine Extended-Release (XR), an antiretroviral medication used in the treatment of HIV-1 infection. The drug is produced by organizations like Vedanta Pharmaceuticals and is marketed as a treatment option with a once-daily dosing schedule.
Market Size and Key Drivers
Global HIV Treatment Market:
The HIV treatment market was valued at approximately $20 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4%, reaching around $25 billion by 2028 (IQVIA, 2022). Rilpivirine’s market share has remained steady, primarily due to its favorable side effect profile.
Major Competitors:
- Efavirenz (EFV): Traditionally dominant, but facing decline due to side effects.
- Dolutegravir (DTG): Increasingly replacing older drugs in first-line regimens.
- Cabotegravir: Injectable long-acting option, gaining prevalence.
Market Penetration of Rilpivirine XR:
Rilpivirine XR accounts for approximately 10-15% of the HIV oral medication market. Its niche lies in patients intolerant to efavirenz or who prefer a once-daily tablet without specific side effects.
Key Factors Influencing Market Growth:
- Increasing HIV diagnoses, estimated at 1.5 million new cases annually globally (WHO, 2022).
- Growing preference for long-acting, less frequent medication regimes.
- Patent exclusivity and generic entry affect pricing and market share.
Price Trends and Projections
Current Pricing Landscape:
- Brand Name (e.g., Edurant, Rilpivirine XR): Around $4,200–$4,800 per month per patient in the US (GoodRx, 2023).
- Generic Versions: Typically 25-50% cheaper, around $2,400–$3,600 per month.
- Reimbursement Impact: Payer schemes heavily influence actual transaction prices, with formularies favoring generics.
Factors Impacting Price Dynamics:
- Patent Expiration: Rilpivirine's primary patents are expected to expire between 2025 and 2027.
- Generic Competition: Entry anticipated within 6-12 months post-patent expiry, potentially reducing prices by 50% or more.
- Market Adoption: Increasing switch to long-acting injectables and new drug classes may limit the growth of oral rilpivirine, affecting price stability.
| Projected Price Trends (Next 5 Years): |
Year |
Estimated Price Range (per patient/month) |
Key Conditions |
| 2023 |
$4,200–$4,800 |
Current prices, patent protections apply |
| 2024 |
$4,000–$4,500 |
Slight reduction expected, pricing pressure from biosimilars |
| 2025 |
$2,800–$3,500 |
Patent expiration, generics enter market |
| 2026 |
$2,400–$3,200 |
Increased generic availability, price erosion |
| 2027 |
$1,800–$2,500 |
Market stabilizes with multiple generics |
Regulatory and Pricing Policies Impacting Future Prices
- US Price Negotiations: CMS and private payers increasingly negotiate discounts for HIV medications.
- International Variations: Prices in emerging markets are generally 50-70% lower, driven by local negotiations and generic availability.
- Pricing Regulation Trends: Countries such as the UK and Canada are implementing stricter cost-effectiveness policies, likely pressuring prices further.
Summary of Market Dynamics
- The current market demonstrates high brand-name pricing, with moderate penetration of generics.
- Patent expiration from 2025 onwards will improve access but significantly reduce revenue.
- Emerging long-acting formulations will compete with oral rilpivirine, potentially reducing demand.
- Reimbursement environments and policies are key to price stability.
Key Takeaways
- The HIV treatment market is growing but increasingly competitive.
- NDC 62011-0406's prices are expected to decline sharply after patent expiry.
- Oral rilpivirine remains relevant in specific patient segments but faces new competition.
- Generic entry will likely reduce prices by at least 50% within two years post-patent expiry.
- Pricing will vary globally, influenced by healthcare policies and negotiation dynamics.
FAQs
1. When will generic versions of rilpivirine XR become available?
Expected 12 months after patent expiry, projected between 2025 and 2027 depending on jurisdiction.
2. How will new long-acting HIV treatments impact rilpivirine's market share?
Long-acting injectables like cabotegravir could reduce demand for oral rilpivirine, especially among patients preferring less frequent dosing.
3. What are the main price differences between brand and generic rilpivirine?
Brand prices hover around $4,200–$4,800 monthly per patient, while generics can be priced 25-50% lower.
4. How do reimbursement policies influence drug prices?
Insurance negotiations and formulary placements drive actual transaction prices, often favoring lower-cost generics.
5. How do international markets affect global pricing?
Regulations and market size create wide variation. Prices in low- and middle-income countries are typically 50-70% lower than in high-income regions.
References
- IQVIA. “Global HIV Market Analysis." 2022.
- WHO. “HIV/AIDS Statistics." 2022.
- GoodRx. “HIV Medication Prices." 2023.
